MYGN - Myriad Genetics - Stock Price & Dividends

Myriad Genetics Inc. is a pioneering genetic testing and precision medicine company that develops and commercializes innovative genetic tests globally. The company's cutting-edge molecular diagnostic tests cater to various medical specialties, including oncology, women's health, and pharmacogenomics.

One of its flagship products is the MyRisk Hereditary Cancer Test, a comprehensive DNA sequencing test that assesses an individual's risk of developing hereditary cancers. Additionally, Myriad offers the BRACAnalysis CDx Germline Companion Diagnostic Test, which helps determine the most effective therapy for patients with metastatic breast, ovarian, pancreatic, and prostate cancer who have deleterious or suspected deleterious germline BRCA variants.

The company's MyChoice CDx Companion Diagnostic Test is a tumor test that identifies homologous recombination deficiency status in patients with ovarian cancer, enabling personalized treatment plans. Myriad also provides the Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis that evaluates the aggressiveness of prostate cancer, and the EndoPredict Breast Cancer Prognostic Test, which assesses the aggressiveness of breast cancer.

In the realm of precision oncology, Myriad offers Precise Tumor, a comprehensive solution that helps tailor treatment strategies to individual patients. The company's Prequel Prenatal Screen is a non-invasive prenatal screening test conducted using maternal blood to detect severe chromosomal disorders in a fetus.

Myriad's Foresight Carrier Screen is a prenatal test that enables future parents to assess their risk of passing on recessive genetic conditions to their offspring. The company's SneakPeek test is a non-invasive blood test that predicts the gender of a fetus. Furthermore, Myriad's GeneSight Psychotropic Mental Health Medication Test is a DNA genotyping test that aids in psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit hyperactivity disorder, and other mental health conditions.

Myriad Genetics has established strategic collaborations with leading organizations, including Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Founded in 1992, the company is headquartered in Salt Lake City, Utah, and is committed to advancing the field of genetic testing and precision medicine.